Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose versus standard-dose heparin during ECMO in critically ill ICU patients
ACTRN12613001324707Phase 2Not yet recruiting
- Sponsor
- The Alfred Hospital
- Start
- Mar 2014
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of heparin in heart failure (HF) and respiratory failure (2 arms), sponsored by The Alfred Hospital. Primary endpoints: Difference in mean daily heparin dose between study groups, Incidence of ECMO circuit thrombosis requiring circuit change and 2 more. Planned start Mar 2014; status: not yet recruiting.
02
Drugs
heparin
03
Conditions
heart failure (HF)respiratory failure
Beyond the preview
Go deeper on ACTRN12613001324707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613001324707.